Skip to main navigation Skip to search Skip to main content

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R2) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

  • David J. Andorsky
  • , Abdulraheem Yacoub
  • , Jacob D. Bitran
  • , Jason Melear
  • , Heather D. Brooks
  • , Kenneth A. Foon
  • , Syed Rizvi
  • , Mary Llorente
  • , Jiahui Li
  • , Jeff P. Sharman
  • Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO
  • University of Kansas
  • Oncology Specialists, SC, Park Ridge, IL
  • Texas Oncology
  • Oncology and Hematology Associates, US Oncology Research, Roanoke, VA
  • Celgene
  • Willamette University

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume128
Issue number22
DOIs
StatePublished - Dec 2 2016
Externally publishedYes

Disciplines

  • Immunology and Infectious Disease
  • Medicine and Health Sciences
  • Oncology
  • Internal Medicine

Cite this